Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $0.74, $0.42 better than the analyst estimate of $0.32. Revenue for the quarter came in at $209 million versus the consensus estimate of $189.72 million.

GUIDANCE:

Halozyme Therapeutics sees FY2022 revenue of $655-685 million, versus the consensus of $661.33 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.